Zylem Biosciences
Research - Chicago, Illinois, United States
Zylem Biosciences Employees
Zylem Biosciences Senior Management
Zylem Biosciences Details
Zylem Biosciences is a startup biotechnology company developing targeted medicines that uniquely mimic features of natural biologics. Zylem's lead compound (ZYL-001) directly targets pathologic cholesterol metabolism in cancer, heart disease and other conditions, and pathologic lipid metabolism in fatty liver disease (FLD) and obesity. ZYL-001 specifically targets a cell surface receptor to simultaneously: modulate cellular and systemic cholesterol and activate the adaptive immune system. ZYL-001 therapies are molecularly tunable and seamlessly interact with natural biological systems with no off-target toxicity. Its first-in-class mechanism of action (MOA) has been validated in small animal models of cancer and obesity.
Zylem Biosciences Technologies
Email Providers
Gmail
Domain Name Services
NSOne
Fonts
Typekit
Other
Google Apps